|
|
|
| Research progress on the effect of SGLT2 inhibitors on osteoporosis in type 2 diabetes mellitus |
| LIU Siqi1 GUO Ying2 ZHANG Chunlan2 ZHAO Na2 WANG Juanli3 |
1.Museum of Chinese Medicine Publicity and Education Promotion Department, Heilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin 150040, China;
2.Department of Endocrinology, the First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin 150040, China; 3.Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China |
|
|
|
Abstract
[Abstract] Osteoporosis is a common complication of diabetes mellitus patients, which seriously affects the quality of life of patients. As a new type of hypoglycemic drug sodium-glucose transporter 2 (SGLT2) inhibitors are widely used in clinical, their effects on bone metabolism have also received widespread attention. Although the drug has good performance in lowering glucose and blood pressure, it may affect bone metabolism and increase the risk of fracture. In order to better guide the clinical use of SGLT2 inhibitors, related factors of osteoporosis caused by SGLT2 inhibitors were described in detail by referring to relevant literatures at home and abroad. The influence of bone metabolism, osteoporosis and even fracture may be related to the imbalance of calcium and phosphorus homeostasis and the increase of parathyroid hormone. However, it is still controversial whether the above consequences are actually related to the use of SGLT2 inhibitors. For diabetic patients with high fracture risk, it should be the consensus of clinicians to fully evaluate the risk of fracture before using these medications.
|
|
|
|
|
|
[1] 史晶晶，胡玲.糖尿病性骨质疏松发病机制的研究进展[J].实用临床医学，2017，18（8）：97-100，104.
[2] Yamamoto M，Yamaguchi T，Yamauchi M，et al. Low serum level of the endogenous secretory receptor for advanced glycation end products（esRAGE）is a risk factor for prevalentvertebral fractures independent of bone mineral density in patients with type 2 diabetes [J]. Diabetes Care，2009，32（12）：2263-2268.
[3] Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1and type 2 diabetes-a meta-analysis [J]. Osteoporos Int，2007，18（4）：427-444.
[4] Cho NH，Shaw JE，Karuranga S，et al. IDF Diabetes Atlas：Global estimates of diabetes prevalence for 2017 and projections for 2045 [J]. Diabetes Res Clin Pract，2018，138：271-281.
[5] Kahn SE，Zinman B，Lachin JM，et al. Rosiglitazone-associated fractures in type 2 diabetes：an Analysis from A Diabetes Outcome Progression Trial（ADOPT）[J]. Diabetes Care，2008，31（5）：845-851.
[6] Zhu ZN，Jiang YF，Ding T. Risk of fracture with thiazolidinediones：an updated meta-analysis of randomized clinical trials [J]. Bone，2014，68：115-123.
[7] Meier C，Schwartz AV，Egger A，et al. Effects of diabetes drugs on the skeleton [J]. Bone，2016，82：93-100.
[8] Schwartz AV. Diabetes，bone and glucose-lowering agents：clinical outcomes [J]. Diabetologia，2017，60（7）：1170-1179.
[9] Gupta V，Canovatchel W，Lokesh BN，et al. Sodium-glucose Cotransporter-2 Inhibitors：Moving Beyond the Glycemic Tre-atment Goal [J]. Indian J Endocrinol Metab，2017，21（6）：909-918.
[10] Polidori D，Sha S，Ghosh A，et al. Validation of a novelmethod for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus [J]. J Clin Endocrinol Metab，2013，98（5）：E867-E871.
[11] Neal B，Perkovic V，Mahaffey KW，et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes [J]. N Engl J Med，2017，377（7）：644-657.
[12] Zinman B，Wanner C，Lachin JM，et al. Empagliflozin，Cardiovascular Outcomes，and Mortality in Type 2 Diabetes [J]. N Engl J Med，2015，373（22）：2117-2128.
[13] Wiviott SD，Raz I，Bonaca MP，et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes [J]. N Engl J Med，2019，380：347-357.
[14] Starup-Linde J，Eriksen SA，Lykkeboe S，et al. Biochemical markers of bone turnover in diabetes patients--a meta-analysis，and a methodological study on the effects of glucose on bone markers [J]. Osteoporos Int，2014，25（6）：1697-1708.
[15] Strollo R，Rizzo P，Spoletini M，et al. HLA-dependent autoantibodies against post-translationally modified collagen type Ⅱ in type 1 diabetes mellitus [J]. Diabetologia，2013，56（3）：563-572.
[16] 梁军波，徐春丽，潘伟波，等.高血糖对成骨细胞增殖分化影响的实验研究[J].医学研究杂志，2012，41（3）：117-120.
[17] Lalla E，Lamster IB，Feit M，et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice [J]. J Clin Invest，2000，105（8）：1117-1124.
[18] Chantelau E，Meyer-Schwickerath R，Klabe K. Downregulation of Serum IGF-1 for Treatment of Early Worsening of Diabetic Retinopathy：A Long-Term Follow-Up of Two Cases [J]. Ophthalmologica，2010，224（4）：243-246.
[19] 张萌萌，毛未贤，马倩倩，等.骨代谢标志物在骨质疏松诊疗中的应用指南（2012 年版）（日本骨质疏松症学会制定）[J].中国骨质疏松杂志，2013，19（7）：645-657．
[20] Bilezikian JP，Watts NB，Usiskin K，et al. Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin [J]. J Clin Endocrinol Metab，2016，101（1）：44-51.
[21] Ljunggren O，Bolinder J，Johansson L，et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin [J]. Diabetes Obes Metab，2012，14（11）：990-999.
[22] Bolinder J，Ljunggren O，Johansson L，et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin [J]. Diabetes Obes Metab，2014，16（2）：159-169.
[23] 乾贝贝，闫彩凤.SGLTs抑制剂对骨代谢的影响及其机制[J].国际内分泌代谢杂志，2019，39（6）：422-425，428.
[24] Trujillo JM，Nuffer WA. Impact of sodium-glucose cotransporter 2 inhibitors on nonglycemicout-comes in patients with type 2 diabetes [J]. Pharmacotherapy，2017， 37（4）：481-491.
[25] Taylor SI，Blau JE，Rother KI. Possible adverse effects of SGLT2 inhibitors on bone [J]. Lancet Diabetes Endocrinol，2015，3（1）：8-10.
[26] Liu ES，Martins JS，Raimann A，et al. 1，25-Dihydroxyvitamin D Alone Improves Skeletal Growth，Microarchitecture，and Strength ina Murine Model of XLH，Despite Enhanced FGF23 Expression [J]. J Bone Miner Res，2016，31（5）：929-939.
[27] Blau JE，Taylor SI. Adverse effects of SGLT2 inhibitors on bone [J]. Nat Rev Nephrol，2018，14（8）：473-474.
[28] Blau JE，Bauman V，Conway EM，et al. Canagliflozin triggers the FGF23/1，25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized cross-over study [J]. JCI Insight，2018，3（8）：e99123.
[29] de Jong MA，Petrykiv SI，Laverman GD，et al. Effects of dapagliflozin on circulating markers of phos-phate homeostasis [J]. Clin J Am Soc Nephrol，2019，14（1）：66-73.
[30] Kohler S，Zeller C，Iliev H，et al. Safety and Tolerability of Empagliflozin in Patientswith Type 2 Diabetes：Pooled Analysis of PhaseⅠ-Ⅲ Clinical Trials [J]. Adv Ther，2017，34（7）：1707-1726.
[31] Adimadhyam S，Lee TA，Calip GS，et al. Sodium-glucose co-transporter 2 inhibitors and the risk of fractures：A propensity score-matched cohort study [J]. Pharmacoepidemiol Drug Saf，2019，28（12）：1629-1639.
[32] Watts NB，Bilezikian JP，Usiskin K，et al. Effects of Canag-liflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus [J]. J Clin Endocrinol Metab，2016，101（1）：157-166.
[33] Perkovic V，Jardine MJ，Neal B，et al. CREDE-NCE Trial Investigators. Canagliflozin and renal outcomes in diabetic nephropathy [J]. N Engl J Med，2019，380（24）：2295-2306.
[34] McMurray JJV，Solomon SD，Inzucchi SE，et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [J]. N Engl J Med，2019，381（21）：1995-2008.
[35] Kohan DE，Fioretto P，Tang W，et al. Long term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but doesnot improve glycemic control [J]. Kidney Int，2014，85（4）：962-971.
[36] Kinduryte Schorling O，Clark D，Zwiener I，et al. Pooled Safety and Tolerability Analysis of Empagliflozin in Patientswith Type 2 Diabetes Mellitus [J]. Adv Ther，2020， 37（8）：3463-3484. |
|
|
|
